Vasopressin

Generic Name: Vasopressin

Brand Names: Vasostrict

Drug Type: Small Molecule

Chemical Formula: C_₉₂H_₁₃₀N_₂₈O_₂₄S_₄

CAS Number: 11000-17-2

Unique Ingredient Identifier: Y87Y826H08

Background: Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour. Vasopressin is very similar to oxytocin, differing in the third and eighth amino acids. Despite a wide variety of functions, exogenous vaso...

Indication: 1.诊断和治疗由于缺乏抗利尿激素而引起的尿崩症，也用于其他药物效果不佳的腹部肌肉松弛；

2.脑外科手术后或头颅创伤后多尿的初期治疗；

3.用于食管、胃肠道消化道疾病的急性大出血的辅助治疗。

Associated Conditions: Acute Circulatory Failure

Associated Therapies: Dental Local Anesthesia

Clinical Trials

Trauma patients could be enrolled without consent in study of drugs to prevent blood loss

Hennepin Healthcare seeks permission to enroll car-crash victims in a clinical trial of two drugs reducing blood loss, aiming to determine if earlier treatment during transport improves survival rates. The study, part of the LITES Network, requires a federal exception for informed consent due to patient unconsciousness. Patients will receive either the drugs or a placebo, with outcomes assessed immediately and 30 days post-injury. The hospital seeks community feedback before final approval from oversight boards.

biospace.com

3 months ago

BioVie Receives Notice of Allowance for United States Patent Application Covering Novel

BioVie secures US patent for its room-temperature stable terlipressin liquid formulation, offering a patient-centric treatment for cirrhosis and ascites, with patents also secured in India and Chile, and pending in nine additional markets.

Vasopressin

Trauma patients could be enrolled without consent in study of drugs to prevent blood loss

BioVie Receives Notice of Allowance for United States Patent Application Covering Novel

Drug Development Updates